Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Cara Therapeutics, Inc.

Cara Therapeutics is a biopharmaceutical company focused on developing treatments for pruritus (itching), particularly for patients with chronic kidney disease undergoing hemodialysis.

Cara Therapeutics

Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is developing an oral formulation of difelikefalin, a selective, peripherally acting, non-scheduled kappa opioid receptor agonist, for the treatment of chronic pruritus associated with notalgia paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back for which there are no FDA-approved therapies. The Company is conducting a Phase 2/3 clinical program in NP with topline results of the dose-finding portion expected in the third quarter of 2024. Cara Therapeutics also developed an IV formulation of difelikefalin, which is approved in the United States, EU, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Devon Park BioVentures

Connecticut Innovations

Alta Partners

Ascent Biomedical Ventures

MVM Life Science Partners

Mitsubishi Corporation

Rho Capital Partners

Scottish Widows Investment Partnership

June 3rd is National Itch Day! At Cara Therapeutics, we understand that #pruritus is more than just an #itch for the millions of people who suffer from the burdensome condition. Chronic pruritus can be all-consuming and have a significant impact on overall well-being.

To learn how we’re working to transform the way pruritus is treated, visit www.CaraTherapeutics.com. #NationalItchDay

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023 
https://lnkd.in/eaUj8FW8

Cara Therapeutics Reports First Quarter 2024 Financial Results https://lnkd.in/ehp6ZXKw

Today we honor the women and men who lost their lives while serving our nation. We will always remember their sacrifices for our freedom.

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 https://lnkd.in/eGKrm2U8

Our Cara Culture Club recently sponsored a school supply drive for SPEF - Stamford Public Education Foundation and gathered donations for K.T. Murphy Elementary School. We wish all the students and teachers a healthy and productive school year! #Stamford #CaraCares

NASDAQ:CARA

Cara Therapeutics

Last Close

0.28

25/09 14:34

Market Cap

15.64M

Beta: 0.88

Volume Today

25.93K

Avg: 670.33K

PE Ratio

−0.27

PFCF: −0.32